Avalara to Present at Upcoming Investor Conferences
Get Alerts AVLR Hot Sheet
Join SI Premium – FREE
SEATTLE--(BUSINESS WIRE)-- Avalara, Inc. (NYSE: AVLR), a leading provider of tax compliance automation for businesses of all sizes, today announced the following upcoming investor conference presentations.
Co-Founder and Chief Executive Officer Scott McFarlane will present at:
- J.P. Morgan Global Technology, Media and Communications Conference on Tuesday, May 24, 2022, at 11:30 a.m. ET (8:30 a.m. PT).
- BofA Securities Global Technology Conference on Thursday, June 9, 2022, at 12:30 p.m. PT (3:30 p.m. ET).
Chief Financial Officer Ross Tennenbaum will present at:
- Needham Technology and Media Conference on Monday, May 16, 2022, at 11:00 a.m. ET (8:00 a.m. PT).
- William Blair Growth Stock Conference on Tuesday, June 7, 2022, at 4:00 p.m. CT (2:00 p.m. PT).
Live webcasts of the presentations will be available on the Avalara investor relations website at investor.avalara.com. Archived replays will be made available for a limited time at the same location following the presentations.
About Avalara, Inc.
Avalara helps businesses of all sizes get tax compliance right. In partnership with leading ERP, accounting, ecommerce, and other financial management system providers, Avalara delivers cloud-based compliance solutions for various transaction taxes, including sales and use, VAT, GST, excise, communications, lodging, and other indirect tax types. Headquartered in Seattle, Avalara has offices across the U.S. and around the world in Brazil, Europe, and India. More information at www.avalara.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005728/en/
Investor Contact
Jennifer Gianola
Avalara
[email protected]
650-499-9837
Media Contact
Tommy Morgan
Avalara
[email protected]
540-448-7551
Source: Avalara, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- Crypto News: Oil Ends the Week Near $117 as Bitcoin Holds Around $80K and Remittix Plans a 300M RTX Burn
- Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 202
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
William Blair, JPMorgan, Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share